In this video, Paolo Tarantino, MD, of the Dana-Farber Cancer Institute in Boston, provides an overview of key updates in breast cancer from the recent American Society of Clinical Oncology (ASCO) annual meeting, including the NATALEE and a retrospective analysis evaluating the sequencing of antibody-drug conjugates.
Following is a transcript of his remarks:
I think the highlight of the Congress was the NATALEE phase III trial. This was a trial of adjuvant ribociclib [Kisqali] for 3 years for patients with hormone receptor-positive, high-risk, early-stage breast cancer. And interestingly, we have already an adjuvant CDK[4/6 inhibitor] approved, that is abemaciclib [Verzenio] based on the monarchE data, but only for patients with node-positive disease. Whereas in NATALEE, there were also patients with high-risk, node-negative disease included, which is a very large population.
And it was important to see in this trial, the iDFS [invasive disease-free survival] curves diverge. And so there seemed to be a benefit at 2 and 3 years with the use …
![New 2023/2024 COVID-19 Vaccine [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_168201_0_0jpg.jpg)
![Stars of Pink Fashion Show [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_168005_0_snapshot62jpg.jpg)
![Susan G. Komen Race for the Cure 2023 celebrates Linda Palenske [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_166560_0_03057c8ba2a84e51a82d06d18a2ba5261140x641jpg.jpg)
![Woman battles breast cancer while mourning the loss of her son [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_166170_0_5afcb2e9c9594b5baf55187c7a2c84bf1140x641jpg.jpg)